GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » EV-to-EBITDA
中文

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) EV-to-EBITDA

: -3.97 (As of Today)
View and export this data going back to 2006. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, EOM Pharmaceutical Holdings's enterprise value is $22.42 Mil. EOM Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 was $-5.65 Mil. Therefore, EOM Pharmaceutical Holdings's EV-to-EBITDA for today is -3.97.

The historical rank and industry rank for EOM Pharmaceutical Holdings's EV-to-EBITDA or its related term are showing as below:

IMUC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.63   Med: 0   Max: 0
Current: -3.97

IMUC's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.005 vs IMUC: -3.97

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), EOM Pharmaceutical Holdings's stock price is $0.1979. EOM Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 was $-4.732. Therefore, EOM Pharmaceutical Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


EOM Pharmaceutical Holdings EV-to-EBITDA Historical Data

The historical data trend for EOM Pharmaceutical Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.24 -2.60 -0.89 0.21 -0.51

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.15 -0.51 -0.61 -1.42

Competitive Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's EV-to-EBITDA falls into.



EOM Pharmaceutical Holdings EV-to-EBITDA Calculation

EOM Pharmaceutical Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=22.416/-5.65
=-3.97

EOM Pharmaceutical Holdings's current Enterprise Value is $22.42 Mil.
EOM Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

EOM Pharmaceutical Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.1979/-4.732
=At Loss

EOM Pharmaceutical Holdings's share price for today is $0.1979.
EOM Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.732.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


EOM Pharmaceutical Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077